ANL
Adlai Nortye Ltd.
Price Chart
Latest Quote
$9.95
-1.05 (-9.55%)
Current Price
| Previous Close | $11.00 |
| Open | $11.43 |
| Day High | $11.43 |
| Day Low | $9.90 |
| Volume | 147,120 |
Stock Information
| Shares Outstanding | 58.73M |
| Total Debt | $26.38M |
| Cash Equivalents | $8.96M |
| Revenue | $5.00M |
| Net Income | $-35.53M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $640.76M |
| EPS (TTM) | $-1.11 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.21B |
| Sales | $5.00M |
| Income | $-35.53M |
| Book/sh | $-0.21 |
| Cash/sh | $0.15 |
| Employees | 109 |
Financial Ratios
| Quick Ratio | 0.22 |
| Current Ratio | 0.65 |
Returns & Margins
| ROA | -42.22% |
| ROE | -414.01% |
| Gross Margin | 100.00% |
| Operating Margin | -330.48% |
Ownership
| Insider Ownership | 5.66% |
| Institutional Ownership | 24.53% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -25.19 |
| P/S | 128.15 |
| P/B | -47.84 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $28.60 |
Technical Indicators
| SMA20 | $11.96 |
| SMA50 | $12.25 |
| SMA200 | $5.70 |
| RSI | 27.92 |
| ATR | 1.2992 |
| Shares Float | 55.84M |
| Short Float | 5.28% |
| Short Ratio | 6.42 |
| Volatility | 0.99 |
| Rel Volume | 1.01 |
Performance History
| Week | -16.67% |
| Month | -30.27% |
| Quarter | +11.67% |
| 6 Months | +631.62% |
| YTD | +621.01% |
| Year | +485.29% |
| 10 Years | -33.67% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $9.95 | 147,100 |
| 2026-06-04 | $11.00 | 98,000 |
| 2026-06-03 | $11.26 | 229,900 |
| 2026-06-02 | $11.58 | 71,700 |
| 2026-06-01 | $12.03 | 151,600 |
| 2026-05-29 | $11.94 | 105,600 |
| 2026-05-28 | $11.30 | 87,600 |
| 2026-05-27 | $11.00 | 72,200 |
| 2026-05-26 | $11.35 | 61,500 |
| 2026-05-22 | $11.92 | 24,200 |
| 2026-05-21 | $11.56 | 96,500 |
| 2026-05-20 | $11.36 | 262,700 |
| 2026-05-19 | $10.70 | 354,100 |
| 2026-05-18 | $11.61 | 344,000 |
| 2026-05-15 | $13.51 | 90,700 |
| 2026-05-14 | $13.86 | 122,200 |
| 2026-05-13 | $13.94 | 42,100 |
| 2026-05-12 | $13.15 | 133,900 |
| 2026-05-11 | $12.96 | 187,300 |
| 2026-05-08 | $13.28 | 227,100 |
| 2026-05-07 | $13.70 | 183,600 |
| 2026-05-06 | $14.27 | 242,400 |
About Adlai Nortye Ltd.
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer. The company also develops AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RAS-mutant cancers, including pancreatic, lung, and colorectal adenocarcinomas; AN4035, a proprietary CEACAM5-targeting antibody drug conjugate designed to deliver potent anti-tumor activity with an improved therapeutic window; and AN8025, a tri-specific antibody fusion protein which is in phase Ia clinical trial to treat advanced tumors. In addition, it develops AN4005, a small-molecule PD-L1 inhibitor that demonstrates antitumor activity by the blockade of PD-1/PD-L1 interaction which is in phase 1b clinical trial to activate cancer immunity. Further, the company is involved in technology transfer and consulting services business. Adlai Nortye Ltd. was founded in 2004 and is headquartered in North Brunswick, New Jersey.
đ° Latest News
Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's What You Should Know
Zacks âĸ 2026-05-20T16:00:05Z
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
Zacks âĸ 2026-05-14T13:40:03Z
Here's Why Adlai Nortye Ltd. Sponsored ADR (ANL) Is a Great 'Buy the Bottom' Stock Now
Zacks âĸ 2026-05-11T13:55:02Z
H.C. Wainwright Sees âPotential Best-in-Class Potencyâ for Adlai Nortyeâs (ANL) Lead Asset, Lifts PT
Insider Monkey âĸ 2026-05-01T08:18:47Z
Adlai Nortye (ANL): 10 Tiny Stocks That Are On Fire Right Now
Insider Monkey âĸ 2026-04-29T17:00:51Z
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2026-04-28T13:40:04Z
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2026-04-10T13:40:03Z
Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's Why
Zacks âĸ 2026-03-19T16:00:04Z
Wall Street Set to Open Lower Friday as Investors React to Trump's Choice of Warsh as Fed Chair
MT Newswires âĸ 2026-01-30T14:14:21ZInvestors Calmed by Trump's Choice of Warsh as Fed Chair, Look Ahead to Inflation Data
MT Newswires âĸ 2026-01-30T12:59:40Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $5,000,000 | $0 | $0 | $0 |
| Operating Revenue | $5,000,000 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $1,488,000 | $1,944,000 | $791,000 | $433,000 |
| Total Expenses | $40,698,000 | $52,928,000 | $72,551,000 | $67,270,000 |
| Other Income Expense | $1,701,000 | $3,003,000 | $-35,886,000 | $8,913,000 |
| Other Non Operating Income Expenses | $1,703,000 | $3,007,000 | $-35,948,000 | $7,879,000 |
| Net Non Operating Interest Income Expense | $-1,531,000 | $-1,944,000 | $-791,000 | $-433,000 |
| Total Other Finance Cost | $43,000 | - | - | - |
| Interest Expense Non Operating | $1,488,000 | $1,944,000 | $791,000 | $433,000 |
| Operating Expense | $40,698,000 | $52,928,000 | $72,551,000 | $67,270,000 |
| Other Operating Expenses | $-396,000 | $-1,940,000 | $-890,000 | $-259,000 |
| General And Administrative Expense | $7,785,000 | $9,443,000 | $14,824,000 | $12,430,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-35,528,000 | $-51,869,000 | $-109,228,000 | $-58,790,000 |
| Net Interest Income | $-1,531,000 | $-1,944,000 | $-791,000 | $-433,000 |
| Normalized Income | $-35,529,000 | $-51,869,000 | $-109,290,000 | $-59,824,000 |
| Net Income From Continuing And Discontinued Operation | $-35,528,000 | $-51,869,000 | $-109,228,000 | $-58,790,000 |
| Total Operating Income As Reported | $-35,698,000 | $-52,928,000 | $-72,551,000 | $-67,270,000 |
| Net Income Common Stockholders | $-35,528,000 | $-51,869,000 | $-109,228,000 | $-58,790,000 |
| Net Income | $-35,528,000 | $-51,869,000 | $-109,228,000 | $-58,790,000 |
| Net Income Including Noncontrolling Interests | $-35,528,000 | $-51,869,000 | $-109,228,000 | $-58,790,000 |
| Net Income Continuous Operations | $-35,528,000 | $-51,869,000 | $-109,228,000 | $-58,790,000 |
| Pretax Income | $-35,528,000 | $-51,869,000 | $-109,228,000 | $-58,790,000 |
| Earnings From Equity Interest | $-3,000 | $-4,000 | $0 | $0 |
| Operating Income | $-35,698,000 | $-52,928,000 | $-72,551,000 | $-67,270,000 |
| Depreciation Amortization Depletion Income Statement | $476,000 | $510,000 | $465,000 | $609,000 |
| Depreciation And Amortization In Income Statement | $476,000 | $510,000 | $465,000 | $609,000 |
| Interest Income | - | - | $62,000 | $550,000 |
| Interest Income Non Operating | - | - | $62,000 | $550,000 |
| Per Share | ||||
| Diluted EPS | $-1.11 | $-1.62 | $-7.56 | $-1.59 |
| Basic EPS | $-1.11 | $-1.62 | $-7.56 | $-1.59 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-32,628,000 | $-48,055,000 | $-106,277,000 | $-57,350,000 |
| Total Unusual Items | $1,000 | - | $62,000 | $1,034,000 |
| Total Unusual Items Excluding Goodwill | $1,000 | - | $62,000 | $1,034,000 |
| Reconciled Depreciation | $1,413,000 | $1,870,000 | $2,222,000 | $2,041,000 |
| EBITDA (Bullshit earnings) | $-32,627,000 | $-48,055,000 | $-106,215,000 | $-56,316,000 |
| EBIT | $-34,040,000 | $-49,925,000 | $-108,437,000 | $-58,357,000 |
| Diluted Average Shares | $31,974,472 | $31,925,569 | $14,447,356 | $36,900,268 |
| Basic Average Shares | $31,974,472 | $31,925,569 | $14,447,356 | $36,900,268 |
| Diluted NI Availto Com Stockholders | $-35,528,000 | $-51,869,000 | $-109,228,000 | $-58,790,000 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Gain On Sale Of Security | $1,000 | - | $62,000 | $1,034,000 |
| Research And Development | $32,833,000 | $44,915,000 | $58,152,000 | $54,490,000 |
| Selling General And Administration | $7,785,000 | $9,443,000 | $14,824,000 | $12,430,000 |
| Other Gand A | $2,977,000 | $3,449,000 | $8,651,000 | $4,230,000 |
| Salaries And Wages | $4,808,000 | $5,994,000 | $6,173,000 | $8,200,000 |
Fetched: 2026-06-02
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-8,341,000 | $25,445,000 | $74,983,000 | $-241,382,000 |
| Total Assets | $34,433,000 | $71,270,000 | $130,189,000 | $72,594,000 |
| Total Non Current Assets | $7,541,000 | $7,206,000 | $28,994,000 | $6,291,000 |
| Other Non Current Assets | $253,000 | $304,000 | $282,000 | $327,000 |
| Goodwill And Other Intangible Assets | $19,000 | $40,000 | $63,000 | $89,000 |
| Other Intangible Assets | $19,000 | $40,000 | $63,000 | $89,000 |
| Current Assets | $26,892,000 | $64,064,000 | $101,195,000 | $66,303,000 |
| Restricted Cash | $15,730,000 | $0 | - | - |
| Prepaid Assets | $1,716,000 | $1,981,000 | $2,337,000 | $1,912,000 |
| Receivables | $1,390,000 | $1,174,000 | $359,000 | $346,000 |
| Other Receivables | $907,000 | $250,000 | $224,000 | $246,000 |
| Taxes Receivable | $468,000 | $910,000 | $135,000 | $100,000 |
| Cash Cash Equivalents And Short Term Investments | $8,056,000 | $60,909,000 | $98,499,000 | $64,045,000 |
| Cash And Cash Equivalents | $8,056,000 | $60,902,000 | $91,492,000 | $42,758,000 |
| Cash Financial | $8,056,000 | $60,902,000 | $91,492,000 | - |
| Non Current Prepaid Assets | - | $304,000 | $0 | $0 |
| Investmentin Financial Assets | - | $0 | $24,849,000 | $0 |
| Non Current Accounts Receivable | - | - | - | - |
| Debt | ||||
| Net Debt | $16,526,000 | - | - | - |
| Total Debt | $26,376,000 | $27,226,000 | $31,548,000 | $6,544,000 |
| Long Term Debt And Capital Lease Obligation | $1,127,000 | $425,000 | $469,000 | $1,236,000 |
| Current Debt And Capital Lease Obligation | $25,249,000 | $26,801,000 | $31,079,000 | $5,308,000 |
| Current Debt | $24,582,000 | $26,330,000 | $30,357,000 | $4,307,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $42,755,000 | $45,785,000 | $55,143,000 | $313,887,000 |
| Total Non Current Liabilities Net Minority Interest | $1,127,000 | $425,000 | $5,469,000 | $1,236,000 |
| Current Liabilities | $41,628,000 | $45,360,000 | $49,674,000 | $312,651,000 |
| Current Deferred Liabilities | $0 | $5,000,000 | $0 | - |
| Payables And Accrued Expenses | $16,379,000 | $13,559,000 | $18,595,000 | $16,975,000 |
| Payables | $13,235,000 | $10,496,000 | $14,781,000 | $13,353,000 |
| Other Payable | $579,000 | $275,000 | $303,000 | $255,000 |
| Total Tax Payable | $18,000 | $75,000 | $130,000 | - |
| Accounts Payable | $12,638,000 | $10,146,000 | $14,348,000 | $13,098,000 |
| Non Current Deferred Liabilities | - | $0 | $5,000,000 | - |
| Other Current Liabilities | - | - | - | $290,368,000 |
| Derivative Product Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $-8,322,000 | $25,485,000 | $75,046,000 | $-252,273,000 |
| Total Equity Gross Minority Interest | $-8,322,000 | $25,485,000 | $75,046,000 | $-241,293,000 |
| Stockholders Equity | $-8,322,000 | $25,485,000 | $75,046,000 | $-241,293,000 |
| Other Equity Interest | $21,592,000 | $20,311,000 | $18,018,000 | $13,688,000 |
| Gains Losses Not Affecting Retained Earnings | $-4,346,000 | $-4,535,000 | $-4,241,000 | $-4,159,000 |
| Retained Earnings | $-464,846,000 | $-429,318,000 | $-377,449,000 | $-268,221,000 |
| Long Term Equity Investment | $4,249,000 | $4,157,000 | $0 | - |
| Preferred Stock Equity | - | - | - | $10,980,000 |
| Preferred Securities Outside Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $176,221,572 | $110,700,803 | $110,700,805 | $110,700,805 |
| Share Issued | $176,221,572 | $110,700,803 | $110,700,805 | $110,700,805 |
| Tangible Book Value | $-8,341,000 | $25,445,000 | $74,983,000 | $-252,362,000 |
| Invested Capital | $16,260,000 | $51,815,000 | $105,403,000 | $-247,966,000 |
| Working Capital | $-14,736,000 | $18,704,000 | $51,521,000 | $-246,348,000 |
| Capital Lease Obligations | $1,794,000 | $896,000 | $1,191,000 | $2,237,000 |
| Total Capitalization | $-8,322,000 | $25,485,000 | $75,046,000 | $-241,293,000 |
| Foreign Currency Translation Adjustments | $-4,346,000 | $-4,535,000 | $-4,241,000 | $-4,159,000 |
| Additional Paid In Capital | $439,266,000 | $439,016,000 | $438,707,000 | $6,415,000 |
| Capital Stock | $12,000 | $11,000 | $11,000 | $10,984,000 |
| Common Stock | $12,000 | $11,000 | $11,000 | $4,000 |
| Long Term Capital Lease Obligation | $1,127,000 | $425,000 | $469,000 | $1,236,000 |
| Current Deferred Revenue | $0 | $5,000,000 | $0 | - |
| Current Capital Lease Obligation | $667,000 | $471,000 | $722,000 | $1,001,000 |
| Line Of Credit | $24,582,000 | $26,330,000 | $30,357,000 | $4,307,000 |
| Current Accrued Expenses | $3,144,000 | $3,063,000 | $3,814,000 | $3,622,000 |
| Investments And Advances | $4,249,000 | $4,157,000 | $24,849,000 | $0 |
| Net PPE | $3,020,000 | $2,705,000 | $3,800,000 | $5,875,000 |
| Accumulated Depreciation | $-4,453,000 | $-3,637,000 | $-3,944,000 | $-2,830,000 |
| Gross PPE | $7,473,000 | $6,342,000 | $7,744,000 | $8,705,000 |
| Leases | $2,466,000 | $2,241,000 | $2,519,000 | $2,532,000 |
| Other Properties | $262,000 | $257,000 | $228,000 | $276,000 |
| Machinery Furniture Equipment | $2,944,000 | $2,889,000 | $3,865,000 | $3,811,000 |
| Buildings And Improvements | $1,801,000 | $955,000 | $1,132,000 | $2,086,000 |
| Properties | $0 | $0 | $0 | $0 |
| Duefrom Related Parties Current | $15,000 | $14,000 | $0 | - |
| Other Short Term Investments | $0 | $7,000 | $7,007,000 | $21,287,000 |
| Preferred Stock | - | $0 | $0 | $10,980,000 |
| Non Current Deferred Revenue | - | $0 | $5,000,000 | - |
| Available For Sale Securities | - | - | $24,849,000 | - |
Fetched: 2026-06-02
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-33,639,000 | $-51,989,000 | $-56,852,000 | $-44,491,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-33,452,000 | $-51,819,000 | $-56,652,000 | $-43,223,000 |
| Cash Flow From Continuing Operating Activities | $-33,452,000 | $-51,819,000 | $-56,652,000 | $-43,223,000 |
| Operating Gains Losses | $2,000 | $27,000 | $-62,000 | $-557,000 |
| Investing Activities | ||||
| Capital Expenditure | $-187,000 | $-170,000 | $-200,000 | $-1,268,000 |
| Investing Cash Flow | $-15,579,000 | $28,065,000 | $-10,954,000 | $28,376,000 |
| Cash Flow From Continuing Investing Activities | $-15,579,000 | $28,065,000 | $-10,954,000 | $28,376,000 |
| Net Other Investing Changes | - | - | - | $550,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $0 | $91,780,000 | $0 |
| Financing Cash Flow | $-3,812,000 | $-6,579,000 | $116,240,000 | $-6,780,000 |
| Cash Flow From Continuing Financing Activities | $-3,812,000 | $-6,579,000 | $116,240,000 | $-6,780,000 |
| Cash Dividends Paid | $0 | $0 | $0 | $0 |
| Net Common Stock Issuance | $0 | $0 | $91,780,000 | $0 |
| Common Stock Issuance | $0 | $0 | $91,780,000 | $0 |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-40,362,000 | $-49,562,000 | $-25,172,000 | $-14,385,000 |
| Issuance Of Debt | $37,719,000 | $44,702,000 | $50,234,000 | $7,897,000 |
| End Cash Position | $8,056,000 | $60,902,000 | $91,492,000 | $42,758,000 |
| Beginning Cash Position | $60,902,000 | $91,492,000 | $42,758,000 | $64,131,000 |
| Effect Of Exchange Rate Changes | $-3,000 | $-257,000 | $100,000 | $254,000 |
| Changes In Cash | $-52,843,000 | $-30,333,000 | $48,634,000 | $-21,627,000 |
| Interest Paid Cff | $-1,169,000 | $-1,871,000 | $-602,000 | $-292,000 |
| Proceeds From Stock Option Exercised | $0 | $152,000 | $0 | $0 |
| Net Issuance Payments Of Debt | $-2,643,000 | $-4,860,000 | $25,062,000 | $-6,488,000 |
| Net Short Term Debt Issuance | $-2,010,000 | $-3,840,000 | $26,165,000 | $-5,418,000 |
| Short Term Debt Payments | $-39,729,000 | $-48,542,000 | $-24,069,000 | $-13,315,000 |
| Short Term Debt Issuance | $37,719,000 | $44,702,000 | $50,234,000 | $7,897,000 |
| Net Long Term Debt Issuance | $-633,000 | $-1,020,000 | $-1,103,000 | $-1,070,000 |
| Long Term Debt Payments | $-633,000 | $-1,020,000 | $-1,103,000 | $-1,070,000 |
| Interest Received Cfi | $1,000 | $701,000 | $62,000 | $550,000 |
| Net Investment Purchase And Sale | $-15,393,000 | $31,713,000 | $-10,817,000 | $29,077,000 |
| Sale Of Investment | $5,039,000 | $92,259,000 | $21,039,000 | $88,057,000 |
| Purchase Of Investment | $-20,432,000 | $-60,546,000 | $-31,856,000 | $-58,980,000 |
| Net Business Purchase And Sale | $0 | $-4,212,000 | $0 | $0 |
| Purchase Of Business | $0 | $-4,212,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-187,000 | $-137,000 | $-199,000 | $-1,232,000 |
| Sale Of PPE | $0 | $33,000 | $1,000 | $17,000 |
| Purchase Of PPE | $-187,000 | $-170,000 | $-200,000 | $-1,249,000 |
| Change In Working Capital | $-2,286,000 | $-5,540,000 | $6,124,000 | $15,247,000 |
| Change In Other Working Capital | $-5,000,000 | - | $5,000,000 | - |
| Change In Other Current Assets | $51,000 | $-22,000 | $45,000 | $128,000 |
| Change In Payables And Accrued Expense | $2,498,000 | $-5,058,000 | $1,515,000 | $10,773,000 |
| Change In Payable | $2,498,000 | $-5,058,000 | $1,515,000 | $10,773,000 |
| Change In Account Payable | $2,491,000 | $-4,202,000 | $1,252,000 | $10,117,000 |
| Change In Prepaid Assets | $165,000 | $-460,000 | $-436,000 | $4,346,000 |
| Other Non Cash Items | $1,415,000 | $1,243,000 | $791,000 | $433,000 |
| Stock Based Compensation | $1,532,000 | $2,450,000 | $4,330,000 | $6,082,000 |
| Unrealized Gain Loss On Investment Securities | $0 | $0 | $39,171,000 | $-7,679,000 |
| Depreciation Amortization Depletion | $1,413,000 | $1,870,000 | $2,222,000 | $2,041,000 |
| Depreciation And Amortization | $1,413,000 | $1,870,000 | $2,222,000 | $2,041,000 |
| Amortization Cash Flow | $22,000 | $22,000 | $25,000 | $20,000 |
| Amortization Of Intangibles | $22,000 | $22,000 | $25,000 | $20,000 |
| Depreciation | $1,391,000 | $1,848,000 | $2,197,000 | $2,021,000 |
| Earnings Losses From Equity Investments | $3,000 | $4,000 | $0 | $0 |
| Gain Loss On Investment Securities | $-1,000 | - | $-62,000 | $-550,000 |
| Gain Loss On Sale Of PPE | $0 | $23,000 | $0 | $-7,000 |
| Net Income From Continuing Operations | $-35,528,000 | $-51,869,000 | $-109,228,000 | $-58,790,000 |
| Net Intangibles Purchase And Sale | - | $0 | $0 | $-19,000 |
| Purchase Of Intangibles | - | $0 | $0 | $-19,000 |
| Interest Received Cfo | - | $0 | $-62,000 | $-550,000 |
| Interest Paid Cfo | - | $0 | $-62,000 | $-550,000 |
Fetched: 2026-06-02